CXCR4 and WHIM syndrome: The orally bioavailable CXCR4-selective antagonist, X4P-001 (X4-Pharma) has been reported to be well-tolerated and able to increase the ANC and ALC (which increased in greater proportion than the ANC) in a dose-dependent manner during a phase II trial consisting of four WHIM syndrome patients [101].